< div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " >..."> < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " >..." /> < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " >..." />

Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA ® (pembrolizumab) in Advanced Colorectal Cancer

< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Designation Based on Results in Patients with Metastatic Colorectal Cancer with High Levels of Microsatellite Instability < /p > < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA < sup > ® < /sup > (pembrolizumab), the company ’s anti-PD-1 therapy, for the treatment of patients with microsatellite instability high (MSI-H) metastatic colorectal cancer. This is the third Breakthrough Therapy Designation granted for KEYTRUDA. < /p > < div class= " field field-type-text field-field-press-release-language field-fieldpressreleaselanguage " > < div class= " field-label " > Language: < /div > < div class= " field-items " > < div class= " field-item odd " > Englis...
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #cancer #Merck #MRK $MRK colorectal cancer Keytruda MSD NYSE:MRK Source Type: news